Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.

Stem cell transplant is a promising treatment option for patients with myelodysplastic syndrome (MDS). Still, the decision to ...

The phase 2 BRACELET-1 trial demonstrated that the combination of pelareorep and paclitaxel significantly improved outcomes ...

Panelists discuss what the AGAVE-201 study displayed.

Panelists give an overview of Graft-vs-host Disease and the modern landscape of treatment.

Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...